FindTrial
Sign In

Community pharmacist in community pharmacies who are dispensing Anti-Tuberculosis drugs, training will be given to follow the patients to complete the treatment

Evaluate Standard Practice of Availability of Anti-Tuberculosis Drugs used for DOTS in Tuberculosis Patients and its Compliance: A Randomized Controlled Study in Community Pharmacies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017591
Enrollment
350
Registered
2019-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Community Pharmacist as DOTS provider: Training for community Pharmacist to become official DOTS provider Control Intervention1: Community Pharmacist without training: Dispensing of Ant

Sponsors

Dr Uday kumar R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Registered pharmacist 2. Availability of anti-tuberculosis Drugs in the community Pharmacies 3. Consenting to be part of RNTCP-DOTS

Exclusion criteria

Exclusion criteria: 1. Those community pharmacies are not willing to participate

Design outcomes

Primary

MeasureTime frame
1. Evaluating standard practice of availability of anti-tuberculosis drugs used for DOTS in tuberculosis patients in community pharmacies. 2.To engage/ strengthening community pharmacist to partner RNTCP objectives. Timepoint: Six months after the recruitment process is initiated—

Secondary

MeasureTime frame
1. To train and certify community pharmacies as a DOTS provider. 2. To increase the compliance towards anti- tuberculosis drugs- to improve the quality of life. Timepoint: one year—

Countries

India

Contacts

Public ContactDr Uday kumar R

KLE Academy of higher education and research

uk96868735352@gmail.com9686873535

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026